

Andrew J Lloyd

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6031259/publications.pdf>

Version: 2024-02-01

41
papers

3,784
citations

394421

19
h-index

276875

41
g-index

42
all docs

42
docs citations

42
times ranked

7449
citing authors

#	ARTICLE	IF	CITATIONS
1	The QALY at 50: One story many voices. <i>Social Science and Medicine</i> , 2022, 296, 114653.	3.8	6
2	Patient and Caregiver Treatment Preferences in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy: A Discrete Choice Experiment Survey in Five European Countries. <i>Pharmacoeconomics</i> , 2022, 40, 103-115.	3.3	3
3	Estimating health state utilities in hemophagocytic lymphohistiocytosis. <i>Journal of Patient-Reported Outcomes</i> , 2021, 5, 12.	1.9	1
4	How to measure fluctuating impairments in people with MS: development of an ambulatory assessment version of the EQ-5D-5L in an exploratory study. <i>Quality of Life Research</i> , 2021, 30, 2081-2096.	3.1	5
5	Evaluating the conduct and application of health utility studies: a review of critical appraisal tools and reporting checklists. <i>European Journal of Health Economics</i> , 2021, 22, 723-733.	2.8	7
6	Vignette-Based Utilities: Usefulness, Limitations, and Methodological Recommendations. <i>Value in Health</i> , 2021, 24, 812-821.	0.3	39
7	Patient preferences for advanced hepatocellular carcinoma treatment: a multicountry stated preference study. <i>Future Oncology</i> , 2021, 17, 4275-4287.	2.4	12
8	Utility Values Associated with Atypical Hemolytic Uremic Syndrome-Related Attributes: A Discrete Choice Experiment in Five Countries. <i>Pharmacoeconomics</i> , 2021, 39, 901-912.	3.3	6
9	Estimation of the Quality-of-Life Impact of X-Linked Myotubular Myopathy. <i>Journal of Neuromuscular Diseases</i> , 2021, 8, 1047-1061.	2.6	4
10	Validation of a novel patient reported tool to assess the impact of treatment in erythropoietic protoporphyria: the EPP-QoL. <i>Journal of Patient-Reported Outcomes</i> , 2021, 5, 65.	1.9	4
11	Patient and Caregiver Health State Utilities in Tuberosus Sclerosis Complex. <i>PharmacoEconomics - Open</i> , 2021, , 1.	1.8	2
12	Time Trade-Off Utilities for Hereditary Angioedema Health and Caregiver States. <i>PharmacoEconomics - Open</i> , 2021, , 1.	1.8	2
13	Performance of the Toddler and Infant (TANDI) Health-Related Quality of Life Instrument in 3-4-Year-Old Children. <i>Children</i> , 2021, 8, 920.	1.5	0
14	Preferences and Utilities for Treatment Attributes in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy in the United Kingdom. <i>Pharmacoeconomics</i> , 2021, , 1.	3.3	4
15	Health related quality of life utility weights for economic evaluation through different stages of chronic kidney disease: a systematic literature review. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 310.	2.4	25
16	How does the EQ-5D-Y Proxy version 1 perform in 3, 4 and 5-year-old children?. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 149.	2.4	23
17	Cognitive decline may not be adequately captured in economic evaluations of multiple sclerosis: are new treatments being undervalued?. <i>Current Medical Research and Opinion</i> , 2020, 36, 609-611.	1.9	8
18	Estimation of impact of RPE65-mediated inherited retinal disease on quality of life and the potential benefits of gene therapy. <i>British Journal of Ophthalmology</i> , 2019, 103, 1610-1614.	3.9	38

#	ARTICLE	IF	CITATIONS
19	Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden. <i>Pharmacoeconomics</i> , 2019, 37, 845-865.	3.3	46
20	Identification, Review, and Use of Health State Utilities in Cost-Effectiveness Models: An ISPOR Good Practices for Outcomes Research Task Force Report. <i>Value in Health</i> , 2019, 22, 267-275.	0.3	98
21	<p>Estimation Of The Quality Of Life Benefits Associated With Treatment For Spinal Muscular Atrophy</p>. <i>ClinicoEconomics and Outcomes Research</i> , 2019, Volume 11, 615-622.	1.9	22
22	What Impact Does Venous Thromboembolism and Bleeding Have on Cancer Patientsâ€™ Quality of Life?. <i>Value in Health</i> , 2018, 21, 449-455.	0.3	58
23	Gains in health utility associated with urinary catheter innovations. <i>Medical Devices: Evidence and Research</i> , 2018, Volume 11, 345-351.	0.8	4
24	Health state utilities in nonâ€“small cell lung cancer: An international study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, e195-e203.	1.1	169
25	Estimating minimal important differences for several scales assessing function and quality of life in patients with attention-deficit/hyperactivity disorder. <i>CNS Spectrums</i> , 2017, 22, 31-40.	1.2	15
26	A discrete choice experiment to determine UK patient preference for attributes of disease modifying treatments in Multiple Sclerosis. <i>Journal of Medical Economics</i> , 2017, 20, 863-870.	2.1	24
27	Special Edition on Utility Measurement, <i>PharmacoEconomics</i> . <i>Pharmacoeconomics</i> , 2017, 35, 5-6.	3.3	13
28	The Weiss Functional Impairment Rating Scale-Parent Form for assessing ADHD: evaluating diagnostic accuracy and determining optimal thresholds using ROC analysis. <i>Quality of Life Research</i> , 2017, 26, 1879-1885.	3.1	38
29	Social preference weights for treatments in Fabry disease in the UK: a discrete choice experiment. <i>Current Medical Research and Opinion</i> , 2017, 33, 23-29.	1.9	5
30	Estimating Health-State Utility for Economic Models in Clinical Studies: An ISPOR Good Research Practices Task Force Report. <i>Value in Health</i> , 2016, 19, 704-719.	0.3	101
31	Health-related quality of life in Parkinsonâ€™s: impact of â€“offâ€“ time and stated treatment preferences. <i>Quality of Life Research</i> , 2016, 25, 1505-1515.	3.1	18
32	Patient preferences and willingness to pay for innovations in intermittent self-catheters. <i>Patient Preference and Adherence</i> , 2015, 9, 381.	1.8	17
33	Health state utility valuation in radioactive iodine-refractory differentiated thyroid cancer. <i>Patient Preference and Adherence</i> , 2015, 9, 1561.	1.8	11
34	Health-Related Quality of Life and Health Utilities in Metastatic Castrate-Resistant Prostate Cancer: A Survey Capturing Experiences from a Diverse Sample of UK Patients. <i>Value in Health</i> , 2015, 18, 1152-1157.	0.3	32
35	Health utilities in relation to treatment response and adverse events in relapsed/refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 1839-1845.	1.3	23
36	Health state utilities for chronic lymphocytic leukemia: importance of prolonging progression-free survival. <i>Leukemia and Lymphoma</i> , 2015, 56, 1320-1326.	1.3	20

#	ARTICLE	IF	CITATIONS
37	A forgotten aspect of the NICE reference case: an observational study of the health related quality of life impact on caregivers of people with multiple sclerosis. BMC Health Services Research, 2013, 13, 346.	2.2	28
38	Interim Scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L Value Sets. Value in Health, 2012, 15, 708-715.	0.3	1,381
39	Conjoint Analysis Applications in Health—a Checklist: A Report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value in Health, 2011, 14, 403-413.	0.3	1,342
40	Patient preferences for asthma therapy: a discrete choice experiment. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2007, 16, 241-248.	2.3	25
41	Impact of cognitive impairment on mild dementia patients and mild cognitive impairment patients and their informants. International Psychogeriatrics, 2006, 18, 151-162.	1.0	104